Showing 2631-2640 of 3315 results for "".
- Genentech: New Vabysmo Data Suggest Greater Retinal Drying vs. Aflibercept in Wet AMD and DMEhttps://modernod.com/news/genentech-new-vabysmo-data-suggest-greater-retinal-drying-vs-aflibercept-in-wet-amd-and-dme/2481564/Genentech announced that post-hoc data indicate treatment with Vabysmo (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in wet age-related macular degeneration (AMD). In diabetic macular edema (DME), post-hoc data suggest V
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- Johnson & Johnson Vision Showcases 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-30-new-sets-of-scientific-data-on-myopia-refractive-technologies-iols-and-more-at-arvo/2481554/Johnson & Johnson Vision announced that it is presenting 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmolog
- Ocugen to Present on Modifier Gene Therapy Platform at ARVO 2023https://modernod.com/news/ocugen-to-present-on-modifier-gene-therapy-platform-at-arvo-2023/2481547/Ocugen announced that the company will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis; OCU410 for the treatment dry age-related macular degeneration (dry AMD); OCU410ST for the treatment of St
- One Million Patients Measured on the Neurolens Measurement Devicehttps://modernod.com/news/one-million-patients-measured-on-the-neurolens-measurement-device/2481546/Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record number
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of Gene Therapy OCU400, for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-12-trial-of-gene-therapy-ocu400-for-the-treatment-of-rp-and-lca/2481534/Ocugen announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) wit
- Haag-Streit Launches New EyeSuite Softwarehttps://modernod.com/news/haag-streit-launches-new-eyesuite-software/2481532/Haag-Streit has announced the launch of EyeSuite software version i9.13, which offers new features for the Eyestar 900’s Anterior Chamber Suite and market-first functionality for the Lenstar Myopia. In addition, it’s existing portfolio of I
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha